Literature DB >> 3314109

Use of erythromycin-rifampin combination in treatment of Rhodococcus equi pneumonia.

C J Hillidge1.   

Abstract

The selection of lipid-soluble antibiotics capable of intracellular penetration is considered critical for the successful treatment of Rhodococcus equi pneumonia and lung abscesses in foals. Two such antibiotics: erythromycin (25 mg kg-1, three times daily) and rifampin (5 mg kg-1 twice daily) have been used in combination for this purpose at the University of Florida since 1981. Positive evidence of R. equi was present on culture of tracheal aspirates in 57 foals, most of which exhibited radiographic evidence of extensive lung abscessation. The duration of therapy ranged from 4 to 9 weeks. Mild diarrhea was sometimes noted, but was never severe enough to require the termination of therapy. No other adverse side effects were apparent. Judged by a return of chest radiographs and hematologic parameters to normal, 50 of the 57 foals were considered to have recovered from the disease; a success rate of 88%.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3314109     DOI: 10.1016/0378-1135(87)90121-0

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  27 in total

1.  Pulmonary abscess due to a rifampin and fluoroquinolone resistant Rhodococcus equi strain in a HIV infected patient.

Authors:  P Nordmann; E Rouveix; M Guenounou; M H Nicolas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-06       Impact factor: 3.267

2.  Comparison of Etest, disk diffusion, and broth macrodilution for in vitro susceptibility testing of Rhodococcus equi.

Authors:  Londa J Berghaus; Steeve Giguère; Kristen Guldbech; Eleanor Warner; Ukachi Ugorji; Roy D Berghaus
Journal:  J Clin Microbiol       Date:  2014-11-05       Impact factor: 5.948

3.  Appearance of multidrug-resistant virulent Rhodococcus equi clinical isolates obtained in China.

Authors:  Huimin Liu; Yutian Wang; Jing Yan; Chengmin Wang; Hongxuan He
Journal:  J Clin Microbiol       Date:  2013-12-04       Impact factor: 5.948

4.  Activity of clarithromycin or rifampin alone or in combination against experimental Rhodococcus equi infection in mice.

Authors:  Alexandra J Burton; Steeve Giguère; Londa J Berghaus; Mary K Hondalus
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

5.  Emergence of rifampin-resistant Rhodococcus equi in an infected foal.

Authors:  S Takai; K Takeda; Y Nakano; T Karasawa; J Furugoori; Y Sasaki; S Tsubaki; T Higuchi; T Anzai; R Wada; M Kamada
Journal:  J Clin Microbiol       Date:  1997-07       Impact factor: 5.948

6.  Characterization of mutations in the rpoB gene associated with rifampin resistance in Rhodococcus equi isolated from foals.

Authors:  M Fines; S Pronost; K Maillard; S Taouji; R Leclercq
Journal:  J Clin Microbiol       Date:  2001-08       Impact factor: 5.948

7.  Concentration of the macrolide antibiotic tulathromycin in broncho-alveolar cells is influenced by comedication of rifampicin in foals.

Authors:  Monica Venner; Jette Peters; Nina Höhensteiger; Birthe Schock; Alexa Bornhorst; Markus Grube; Ulrike Adam; Eberhard Scheuch; Werner Weitschies; Dieter Rosskopf; Heyo K Kroemer; Werner Siegmund
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-12-15       Impact factor: 3.000

8.  Detection of virulent Rhodococcus equi in exhaled air samples from naturally infected foals.

Authors:  G Muscatello; J R Gilkerson; G F Browning
Journal:  J Clin Microbiol       Date:  2009-01-14       Impact factor: 5.948

Review 9.  Use of rifampin in nonstaphylococcal, nonmycobacterial disease.

Authors:  A B Morris; R B Brown; M Sands
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

Review 10.  The medically important aerobic actinomycetes: epidemiology and microbiology.

Authors:  M M McNeil; J M Brown
Journal:  Clin Microbiol Rev       Date:  1994-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.